NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization429.7 mln
Float75.00 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
10.07
Highly suspicious
1-Year Forecast
16.38
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
1.04
Elevated leverage
ROE
-763
Deeply negative
Business Description
Verastem is a US-based biopharmaceutical company focused on developing cancer treatments, with its most advanced work centered on two oral drugs ? Avutometinib and Defactinib ? that work by blocking specific signals cancer cells use to grow and spread. The company is running several clinical trials to test these medicines, most notably in patients with recurrent low-grade serous ovarian cancer and cancers driven by KRAS mutations. Verastem works alongside major partners including Chugai Pharmaceutical, Pfizer, and Amgen to develop, manufacture, and commercialize its treatments. Founded in 2010 and based in Needham, Massachusetts, the company continues to expand its pipeline through additional research collaborations targeting hard-to-treat cancers.
